Sign up to save your podcasts
Or
Share What to Know About Bimekizumab for HS: Update from James Q. Del Rosso, DO
Share to email
Share to Facebook
Share to X
Share to email
Share to Facebook
Share to X
Or
What to Know About Bimekizumab for HS: Update from James Q. Del Rosso, DO
Approved late last year to treat HS, bimekizumab was the subject of several publications in 2024, including phase 3 pivotal trial data. AARS President James Q. Del Rosso, DO gives an update on key data considerations. You can watch Dr. Del Rosso's full discussion of trial design, efficacy data, and safety findings online at acneandrosacea.org.
The American Acne and Rosacea Society (AARS) is the only professional society focused on acne, hidradenitis suppurativa, and rosacea. Support AARS by becoming a member!
View all episodes
By American Acne and Rosacea Society (AARS)Approved late last year to treat HS, bimekizumab was the subject of several publications in 2024, including phase 3 pivotal trial data. AARS President James Q. Del Rosso, DO gives an update on key data considerations. You can watch Dr. Del Rosso's full discussion of trial design, efficacy data, and safety findings online at acneandrosacea.org.
The American Acne and Rosacea Society (AARS) is the only professional society focused on acne, hidradenitis suppurativa, and rosacea. Support AARS by becoming a member!